FORMULATION ARTICLES
-
![Financial security, wealth protection, money insurance-GettyImages-2288391875]( "Protecting The Platform: Trade Secret Protection For RNA Biotech Companies")
Protecting The Platform: Trade Secret Protection For RNA Biotech CompaniesAs RNA therapeutics grow more complex and collaborative, trade secrets are becoming an increasingly important part of protecting valuable platform innovation.
-
![Measuring Success GettyImages-1319232417]( "How Should We Measure The True Potency Of RNA Therapeutics?")
How Should We Measure The True Potency Of RNA Therapeutics?An RNA therapeutic can generate a strong molecular signal without producing the intended biological function. Let's look at how best to predict whether the RNA has completed its task.
-
![business model-GettyImages-879532512]( "From Albumin To Oncology: Can Chemical Engineering Unlock Solid Tumor Delivery?")
From Albumin To Oncology: Can Chemical Engineering Unlock Solid Tumor Delivery?We discuss how selective albumin binding improved tumor delivery in preclinical studies and what these findings could mean for the future of siRNA-based cancer therapies.
-
![Human Internal Organs Anatomy-GettyImages-1391174702]( "Beyond GalNAc: Reengineering siRNA For Extrahepatic Delivery")
Beyond GalNAc: Reengineering siRNA For Extrahepatic DeliveryWe discuss why effective extrahepatic delivery remains one of the field's biggest obstacles and how chemical engineering may provide a new path forward.
-
![Asthma inhaler-GettyImages-2240010472]( "Engineering CAR T Cells With mRNA-LNPs: Applying Oncology Learnings To Allergic Diseases")
Engineering CAR T Cells With mRNA-LNPs: Applying Oncology Learnings To Allergic DiseasesTargeted lipid nanoparticles (LNPs) could deliver mRNA encoding a CAR directly to T cells inside a patient with allergic disease. The potential implications extend beyond a single allergic condition.
-
![neuroscience, neuromuscular disorders, pain signals, rehabilitation-GettyImages-2280116713]( "Why Delivery Is Defining The Next Era Of Neuromuscular Therapeutics")
Why Delivery Is Defining The Next Era Of Neuromuscular TherapeuticsEmerging therapies are being designed to safely deliver oligonucleotides to disease-relevant tissues. Delivery is no longer a technical hurdle to overcome but a strategic lever.
FORMULATION VIDEOS
Together, Life Edit Therapeutics’ April Sena and Sanofi’s Troiano share their perspectives on raw material quality & IP-related considerations for managing the supply chain for next-generation RNA modalities.
Unlike conventional predictive biomarkers, which often focus on isolated molecular markers, this strategy integrates spatial metabolomics and genomics, providing a multidimensional perspective.
In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, share their thoughts on the scientific-research and CMC-related reasons that have made the lipid nanoparticle the “darling” of the delivery world for mRNA/RNA products today.
In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery for Strand Therapeutics, outline several examples of foundational research that could provide insights into how we attain more specific cellular uptake of LNPs.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-970394878-genetic-engineering-gene-editing-dna]( "Genome Editing Using mRNA-Lipid Nanoparticles For CAR T Cell Therapy")
Gene delivery platforms must support a diversity of genetic engineering strategies for genomic medicine development. Learn how lipid nanoparticles can accelerate development from discovery to scale-up.
-
![Lipid Nanoparticles GettyImages-1437855772]( "How To Make The Best LNPs")
There are various factors that require careful consideration throughout the process of formulating LNPs and utilizing them for successful mRNA delivery and translation.
-
![GettyImages-1409734937-3d-rendering-rna-dna]( "Current Challenges In The Plasmid DNA Manufacturing Process")
PolyA tail stability shapes mRNA potency, consistency, and manufacturability. Addressing integrity early reduces variability, simplifies workflows, and supports reliable clinical scale‑out.
-
![blood-cell_173710948-thinkstock_450x300]( "Hemophilia - Global Clinical Trial Landscape")
Delve into the clinical landscape of hemophilia, a rare X-linked congenital bleeding disorder, across three key regions of the globe, namely Asia Pacific, Europe, and North America.
-
![GettyImages-1437856375-lnp-lipid-nanoparticle]( "Regulatory Considerations For Excipients Used In Lipid Nanoparticles")
Review the regulatory classification of LNPs, liposomes, and novel excipients as well as specific requirements outlined in regulatory guidance documents and strategies to navigate emerging challenges.
-
![GettyImages-1358868801 antibodies]( "How mRNA Technology Engineers Next-Generation Antibodies")
Monoclonal antibodies (mAbs) stand as pivotal drug products and biochemical reagents in the 21st century. Explore how mRNA-encoded antigens could revolutionize antibody discovery.
-
![GettyImages-2270198779-blue-lipid-nanoparticle-system-delivery]( "Towards A Universal LNP Platform For Multiplex Engineering")
Multiplex engineering of T cells for solid tumors requires precise delivery. Emerging LNP approaches enable co-delivery of RNA and DNA, offering a safer, more scalable path beyond viral vectors.
